FINWIRES · TerminalLIVE
FINWIRES

由于美国3月份批发价格通胀率涨幅低于预期,美元走软,黄金价格上涨。

By

-- 周二早盘,由于美元走软,黄金价格走高。此前美国公布的3月批发价格指数(PPI)涨幅低于预期。 5月交割的黄金期货价格上涨22.90美元,至每盎司4790.30美元。 美国劳工统计局公布的数据显示,经季节性调整后的3月生产者价格指数(PPI)上涨0.5%,与上月持平,远低于Marketwatch此前普遍预期的1.1%。剔除波动较大的食品和能源价格后的核心PPI上涨0.2%,低于2月份的0.5%,也低于市场预期的0.4%。 该机构表示:“3月份加工中间需求产品价格指数上涨的一半以上可归因于柴油价格上涨42.0%。汽油、航空煤油、基础有机化学品、钢铁产品和残渣燃料的价格指数也均有所上涨。” 数据公布后,美元走低,ICE美元指数最新下跌0.37点至98.00,为2月27日以来的最低水平。美国国债收益率基本保持稳定,两年期美国国债收益率上涨0.4个基点至3.787%,十年期美国国债收益率上涨0.3个基点至4.296%。

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD